Flex Pharma Inc. (FLKS) 22.84 $FLKS
Flex Pharma Data Presented at AAN Platform Session
Business Wire - Tue Apr 21, 3:00PM CDT
Click to Tweet this News
FLKS: 22.84 (-1.33)
4 Stocks Spiking on Big Volume
at The Street - Mon Apr 20, 12:28PM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
ES: 49.46 (-0.15), LGF: 31.24 (+0.10), CPLA: 67.67 (+0.79), FLKS: 22.84 (-1.33)
John Winkelman, M.D., Ph.D., Joins Flex Pharma's Scientific Advisory Board
Business Wire - Mon Apr 13, 7:30AM CDT
Click to Tweet this News
FLKS: 22.84 (-1.33)
Jeffrey D. Capello Appointed to Flex Pharma's Board of Directors
Business Wire - Mon Apr 06, 7:30AM CDT
Click to Tweet this News
BSX: 18.41 (+0.10), JNJ: 100.43 (+0.13), CG: 29.75 (+0.36), OVAS: 29.85 (-0.24), FLKS: 22.84 (-1.33), PKI: 51.69 (-0.02)
Flex Pharma Added to Russell 3000(R), Russell 2000(R), and Russell Microcap(R) Indices
Business Wire - Wed Apr 01, 7:30AM CDT
Click to Tweet
FLKS: 22.84 (-1.33)
Flex Pharma reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 6:34AM CDT
FLKS: 22.84 (-1.33)
Flex Pharma Reports Year End 2014 Financial Results
Business Wire - Tue Mar 17, 6:30AM CDT
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today reported financial results for the year ended December 31, 2014 and provided an update on its clinical development and corporate activities.
FLKS: 22.84 (-1.33)
Flex Pharma names Dr Thomas Wessel as CMO
M2 - Tue Mar 17, 3:20AM CDT
Biotechnology company Flex Pharma (NasdaqGM:FLKS) disclosed on Monday the election of Thomas Wessel, MD, PhD as its chief medical officer.
FLKS: 22.84 (-1.33)
Thomas Wessel, M.D., Ph.D., Appointed Chief Medical Officer
Business Wire - Mon Mar 16, 8:00AM CDT
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced the appointment of Thomas Wessel, M.D., Ph.D., as its Chief Medical Officer, reporting to Christoph Westphal M.D., Ph.D., Flex Pharma's President, CEO and Chair. Flex Pharma also announced that Elizabeth Woo, M.B.A., has been promoted to Senior Vice President, Investor Relations and Corporate Communications.
FLKS: 22.84 (-1.33)
Flex Pharma to Report Full Year 2014 Results on March 17, 2015
Business Wire - Tue Mar 10, 8:00AM CDT
Flex Pharma, Inc. (NASDAQ:FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will report its financial results for the year ended December 31, 2014 on Tuesday, March 17, 2015 before the U.S. financial markets open. The Company will host a conference call and webcast at 9:00 a.m. ET to discuss 2014 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874 (International).
FLKS: 22.84 (-1.33)
Flex Pharma reports CEO's stock purchase plan
M2 - Tue Mar 10, 5:40AM CDT
Biotechnology company Flex Pharma (NasdaqGM:FLKS) revealed on Monday the launch of a pre-arranged personal stock purchasing plan for the acquisition of its stock on a non-discretionary basis.
FLKS: 22.84 (-1.33)
Flex Pharma Announces Establishment of Stock Purchase Plan by Chief Executive Officer
Business Wire - Mon Mar 09, 7:30AM CDT
(Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D., has established a pre-arranged personal stock purchasing plan to acquire shares of the Company's stock.
FLKS: 22.84 (-1.33)
Medtronic, Leading Neurostimulation Company, Invests in Flex Pharma IPO
Business Wire - Tue Mar 03, 7:30AM CST
(Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Medtronic invested in the Flex Pharma initial public offering on January 29, 2015.
MDT: 78.01 (+0.93), FLKS: 22.84 (-1.33)
Help for People with Muscle Cramps?
PR Newswire - Wed Feb 18, 6:25PM CST
A new treatment may bring hope for people who suffer from muscle cramps or spasms from neuromuscular disorders, diseases such as multiple sclerosis or simply from nighttime leg cramps that keep people from sleeping, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
FLKS: 22.84 (-1.33)
AAN Selects Flex Pharma Data for Oral Platform Presentation
Business Wire - Wed Feb 18, 3:15PM CST
(Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that the Company's data have been selected for an oral platform presentation at the American Academy of Neurology (AAN) 67th Annual Meeting being held in Washington, D.C. The abstract, titled "Orally-administered TRPV1 and TRPA1 activators inhibit electrically-induced muscle cramps in normal healthy volunteers," will be presented on Tuesday, April 21, 2015, from 3:45 to 4:00 p.m.
FLKS: 22.84 (-1.33)
Flex Pharma announces co-founder Dr Christoph Westphal's appointment to BIO board
M2 - Thu Feb 12, 5:06AM CST
Biotechnology company Flex Pharma (NasdaqGS:FLKS) said on Wednesday that its co-founder Christoph Westphal, MD, PhD has been elected to the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board.
FLKS: 22.84 (-1.33)
Flex Pharma CEO Christoph Westphal, M.D., Ph.D., Joins BIO Emerging Companies Governing Board
Business Wire - Wed Feb 11, 3:00PM CST
(Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Flex Pharma Co-founder and CEO, Christoph Westphal, M.D., Ph.D., has been appointed to the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board. Dr. Westphal was Co-Founder, CEO and lead investor of Acceleron, Alnylam, Flex, Momenta, Sirtis and Verastem.
FLKS: 22.84 (-1.33)
Flex Pharma Announces Closing Of Initial Public Offering
Business Wire - Wed Feb 04, 7:30AM CST
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced the closing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $16.00 per share, resulting in gross proceeds of $86.4 million, before underwriting discounts and commissions. All of the shares in the offering were sold by Flex Pharma. The company's shares began trading on The NASDAQ Global Market on Thursday, January 29, 2015 under the ticker symbol "FLKS."
FLKS: 22.84 (-1.33)
U.S. IPO Weekly Recap: Shake Shack And Spark Spike Over 100% In A Week With 10 IPOs
Renaissance Capital IPO Research - at Seeking Alpha - Sun Feb 01, 7:41AM CST
Ten IPOs raised $1.2 billion in a week dominated by 8 health care IPOs and distinguished by 2 deals that gained over 100% on the first day - fast casual burger chain Shake Shack and gene therapy biotech Spark Therapeutics. There were more health care...
AVGR: 11.66 (+0.23), SHAK: 62.00 (+2.00), ASND: 20.40 (-0.04), HIFR: 31.80 (+0.55), ONCE: 64.79 (-0.25), ENTL: 25.67 (-0.85), ZSAN: 8.87 (-0.18), LENS: 8.00 (+0.63), FLKS: 22.84 (-1.33), TCON: 12.48 (+0.09)
The Absurdity of Flex Pharma IPO: 2 Spices and a Veg Net $86M
at The Street - Thu Jan 29, 6:44AM CST
If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.
VSTM: 9.99 (unch), FLKS: 22.84 (-1.33)
Flex Pharma Data Presented at AAN Platform Session
Business Wire - Tue Apr 21, 3:00PM CDT
Click to Tweet this News
FLKS: 22.84 (-1.33)
4 Stocks Spiking on Big Volume
at The Street - Mon Apr 20, 12:28PM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
ES: 49.46 (-0.15), LGF: 31.24 (+0.10), CPLA: 67.67 (+0.79), FLKS: 22.84 (-1.33)
John Winkelman, M.D., Ph.D., Joins Flex Pharma's Scientific Advisory Board
Business Wire - Mon Apr 13, 7:30AM CDT
Click to Tweet this News
FLKS: 22.84 (-1.33)
Jeffrey D. Capello Appointed to Flex Pharma's Board of Directors
Business Wire - Mon Apr 06, 7:30AM CDT
Click to Tweet this News
BSX: 18.41 (+0.10), JNJ: 100.43 (+0.13), CG: 29.75 (+0.36), OVAS: 29.85 (-0.24), FLKS: 22.84 (-1.33), PKI: 51.69 (-0.02)
Flex Pharma Added to Russell 3000(R), Russell 2000(R), and Russell Microcap(R) Indices
Business Wire - Wed Apr 01, 7:30AM CDT
Click to Tweet
FLKS: 22.84 (-1.33)
Flex Pharma reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 6:34AM CDT
FLKS: 22.84 (-1.33)
Flex Pharma Reports Year End 2014 Financial Results
Business Wire - Tue Mar 17, 6:30AM CDT
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today reported financial results for the year ended December 31, 2014 and provided an update on its clinical development and corporate activities.
FLKS: 22.84 (-1.33)
Flex Pharma names Dr Thomas Wessel as CMO
M2 - Tue Mar 17, 3:20AM CDT
Biotechnology company Flex Pharma (NasdaqGM:FLKS) disclosed on Monday the election of Thomas Wessel, MD, PhD as its chief medical officer.
FLKS: 22.84 (-1.33)
Thomas Wessel, M.D., Ph.D., Appointed Chief Medical Officer
Business Wire - Mon Mar 16, 8:00AM CDT
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced the appointment of Thomas Wessel, M.D., Ph.D., as its Chief Medical Officer, reporting to Christoph Westphal M.D., Ph.D., Flex Pharma's President, CEO and Chair. Flex Pharma also announced that Elizabeth Woo, M.B.A., has been promoted to Senior Vice President, Investor Relations and Corporate Communications.
FLKS: 22.84 (-1.33)
Flex Pharma to Report Full Year 2014 Results on March 17, 2015
Business Wire - Tue Mar 10, 8:00AM CDT
Flex Pharma, Inc. (NASDAQ:FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will report its financial results for the year ended December 31, 2014 on Tuesday, March 17, 2015 before the U.S. financial markets open. The Company will host a conference call and webcast at 9:00 a.m. ET to discuss 2014 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874 (International).
FLKS: 22.84 (-1.33)
Flex Pharma reports CEO's stock purchase plan
M2 - Tue Mar 10, 5:40AM CDT
Biotechnology company Flex Pharma (NasdaqGM:FLKS) revealed on Monday the launch of a pre-arranged personal stock purchasing plan for the acquisition of its stock on a non-discretionary basis.
FLKS: 22.84 (-1.33)
Flex Pharma Announces Establishment of Stock Purchase Plan by Chief Executive Officer
Business Wire - Mon Mar 09, 7:30AM CDT
(Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D., has established a pre-arranged personal stock purchasing plan to acquire shares of the Company's stock.
FLKS: 22.84 (-1.33)
Medtronic, Leading Neurostimulation Company, Invests in Flex Pharma IPO
Business Wire - Tue Mar 03, 7:30AM CST
(Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Medtronic invested in the Flex Pharma initial public offering on January 29, 2015.
MDT: 78.01 (+0.93), FLKS: 22.84 (-1.33)
Help for People with Muscle Cramps?
PR Newswire - Wed Feb 18, 6:25PM CST
A new treatment may bring hope for people who suffer from muscle cramps or spasms from neuromuscular disorders, diseases such as multiple sclerosis or simply from nighttime leg cramps that keep people from sleeping, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
FLKS: 22.84 (-1.33)
AAN Selects Flex Pharma Data for Oral Platform Presentation
Business Wire - Wed Feb 18, 3:15PM CST
(Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that the Company's data have been selected for an oral platform presentation at the American Academy of Neurology (AAN) 67th Annual Meeting being held in Washington, D.C. The abstract, titled "Orally-administered TRPV1 and TRPA1 activators inhibit electrically-induced muscle cramps in normal healthy volunteers," will be presented on Tuesday, April 21, 2015, from 3:45 to 4:00 p.m.
FLKS: 22.84 (-1.33)
Flex Pharma announces co-founder Dr Christoph Westphal's appointment to BIO board
M2 - Thu Feb 12, 5:06AM CST
Biotechnology company Flex Pharma (NasdaqGS:FLKS) said on Wednesday that its co-founder Christoph Westphal, MD, PhD has been elected to the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board.
FLKS: 22.84 (-1.33)
Flex Pharma CEO Christoph Westphal, M.D., Ph.D., Joins BIO Emerging Companies Governing Board
Business Wire - Wed Feb 11, 3:00PM CST
(Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Flex Pharma Co-founder and CEO, Christoph Westphal, M.D., Ph.D., has been appointed to the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board. Dr. Westphal was Co-Founder, CEO and lead investor of Acceleron, Alnylam, Flex, Momenta, Sirtis and Verastem.
FLKS: 22.84 (-1.33)
Flex Pharma Announces Closing Of Initial Public Offering
Business Wire - Wed Feb 04, 7:30AM CST
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced the closing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $16.00 per share, resulting in gross proceeds of $86.4 million, before underwriting discounts and commissions. All of the shares in the offering were sold by Flex Pharma. The company's shares began trading on The NASDAQ Global Market on Thursday, January 29, 2015 under the ticker symbol "FLKS."
FLKS: 22.84 (-1.33)
U.S. IPO Weekly Recap: Shake Shack And Spark Spike Over 100% In A Week With 10 IPOs
Renaissance Capital IPO Research - at Seeking Alpha - Sun Feb 01, 7:41AM CST
Ten IPOs raised $1.2 billion in a week dominated by 8 health care IPOs and distinguished by 2 deals that gained over 100% on the first day - fast casual burger chain Shake Shack and gene therapy biotech Spark Therapeutics. There were more health care...
AVGR: 11.66 (+0.23), SHAK: 62.00 (+2.00), ASND: 20.40 (-0.04), HIFR: 31.80 (+0.55), ONCE: 64.79 (-0.25), ENTL: 25.67 (-0.85), ZSAN: 8.87 (-0.18), LENS: 8.00 (+0.63), FLKS: 22.84 (-1.33), TCON: 12.48 (+0.09)
The Absurdity of Flex Pharma IPO: 2 Spices and a Veg Net $86M
at The Street - Thu Jan 29, 6:44AM CST
If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.
VSTM: 9.99 (unch), FLKS: 22.84 (-1.33)
